Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Valuck, R. J. Articles by Baldessarini, R. J. Search for Related Content PubMed Citation Articles by Valuck, R. J. Articles by Baldessarini, R. J. Health Policy and Legislation Depression Antidepressants

Spillover Effects on Treatment of Adult Depression in Primary Care After FDA Advisory on Risk of Pediatric Suicidality With SSRIs

OBJECTIVE: In 2003, the U.S. Food and Drug Administration (FDA) issued a public health advisory about the risk of suicidality in pediatric patients taking selective serotonin reuptake inhibitors (SSRIs) for depression, and in 2005, the agency mandated a black box warning and medication guide indicating that pediatric and adult patients may be at risk. The authors examine the effects of this pediatric policy on treatment of adult depression in the community. METHOD: An adult cohort with newly diagnosed episodes of depression was created from a large national integrated claims database of managed care plans from October 1998 to September 2005 (N=475,838 unique episodes). Time-series analyses were used to compare the post-FDA advisory trends to the trends during the 5 years preceding the advisory. RESULTS: The rate of diagnosed depression was significantly lower after the advisory than would have been expected on the basis of the preadvisory historical trend. The average percentage of adults with new (versus recurrent) depressive episodes was 88.6% in the preadvisory period (declining at an annual rate of 1.69%), and it decreased significantly to 77.5% (declining more rapidly, at an annual rate of 7.70%). The percentage of adults with depression who did not receive an antidepressant increased from an average of 20% (declining at 0.45% annually) before the policy action to an average of 30% (increasing at an annual rate of 20.6%). The data did not show any compensatory increases in psychotherapy or prescription of atypical antipsychotics or anxiolytics. CONCLUSIONS: The FDA advisory had a significant spillover effect into community treatment for adults with depression, despite the focus of the policy on pediatric patients.

This article has been cited by other articles:

				E. M. Tsapakis*, F. Soldani*, L. Tondo, and R. J. Baldessarini Efficacy of antidepressants in juvenile depression: meta-analysis The British Journal of Psychiatry, July 1, 2008; 193(1): 10 - 17. [Abstract] [Full Text] [PDF]

				L. Y. Katz MD, A. L. Kozyrskyj PhD, H. J. Prior MSc, M. W. Enns MD, B. J. Cox PhD, and J. Sareen MD Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults Can. Med. Assoc. J., April 8, 2008; 178(8): 1005 - 1011. [Abstract] [Full Text] [PDF]

				E. H. Morrato, A. M. Libby, H. D. Orton, F. V. deGruy III, D. A. Brent, R. Allen, and R. J. Valuck Frequency of Provider Contact After FDA Advisory on Risk of Pediatric Suicidality With SSRIs Am J Psychiatry, January 1, 2008; 165(1): 42 - 50. [Abstract] [Full Text] [PDF]

				R. D. GIBBONS Dr. Gibbons Replies Am J Psychiatry, December 1, 2007; 164(12): 1908 - 1910. [Full Text] [PDF]

				R. D. Gibbons, C. H. Brown, K. Hur, S. M. Marcus, D. K. Bhaumik, J. A. Erkens, R. M.C. Herings, and J. J. Mann Early Evidence on the Effects of Regulators' Suicidality Warnings on SSRI Prescriptions and Suicide in Children and Adolescents Am J Psychiatry, September 1, 2007; 164(9): 1356 - 1363. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2007 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us